Research programme: anti-HIV therapy - BioLineRx
Alternative Names: BL-1050Latest Information Update: 07 Feb 2006
At a glance
- Originator Hebrew University of Jerusalem
- Class
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 30 Jan 2006 Discontinued - Preclinical for HIV infections treatment in Israel (unspecified route)
- 18 Jan 2005 Preclinical trials in HIV infections treatment in Israel (unspecified route)